A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-06 and is reviewed periodically as new material appears.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
Storage recommendations for tirzepatide generally specify refrigeration at 2–8 °C to maintain stability. The peptide should be protected from light and kept in its original packaging to prevent aggregation or adsorption. Freezing is not recommended because freeze-thaw cycles can cause aggregation or precipitation. Once dispensed, storage conditions and in-use periods follow product-specific labeling, which may allow room temperature storage for a limited time.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Long-term storage of the solid generally relies on temperatures at or below minus twenty degrees Celsius, while short-term working stocks may be held refrigerated. Light exposure is limited because photodegradation can alter side chains over extended periods. Solutions prepared for analysis are less stable than the dry powder and are typically used within the same working day. Buffer choice matters, since some aqueous conditions favor deamidation or oxidation at specific residues. Stability data are usually generated under defined accelerated conditions and then extrapolated with stated assumptions.
Cannabis had been decriminalised by the Prayut government in 2022, with the move being most supported by the Bhumjaithai Party (BJT) as one of its flagship policies. The Pheu Thai party had run in 2023 on an anti-drug policy and opposed the use of cannabis except for medical use and, under Srettha, had proposed legislation aimed at restricting the use of cannabis. The party's stance on cannabis thus led to tension with the BJT – creating a rift between the two parties which remained in a coalition when Paetongtarn became prime minister. The Thai government had hoped that decriminalising cannabis would turn it into a cash crop. A lack of laws governing cannabis were blamed for the rise in illegal distribution and the creation of a saturated market. Shortly after becoming prime minister, the Ministry of Public Health proposed a new bill on 12 September 2024 restricting cannabis to medical and research reasons. It also proposed the establishment of a Cannabis Control Board (CCB) to regulate the industry. The bill did not pass and Paetongtarn pledged that the government would not reverse its policy on cannabis again. However, by 2025, tourists smuggling cannabis out from Thailand was on the rise. Somsak Thepsuthin, the Minister of Public Health, listed in May that Hong Kong, India, Pakistan and the United Kingdom were the main destinations. On 22 May, the Paetongtarn government announced it planned to introduce new restrictions limiting cannabis usage to individuals (including foreigners) with medical prescriptions from doctors.
==== United States and Canada ==== In the United States and Canada, insects for human consumption are not classified as novel food and the import and sale is permitted. In the United States, insect food products must comply with Food and Drug Administration (FDA) standards and food labeling regulations (including allergy risk labelling). Within the Federal Food, Drug, and Cosmetic Act of 1938 (FD&C Act), the FDA states that "The term 'food' means (1) articles used for food or drink for man or other animals, (2) chewing gum, and (3) articles used for components of any such article." Thus, with insects falling under said category, they must be safe and may not bear any added poisonous or added deleterious substance that is unsafe. Said items may not be prepared, packed, or held under insanitary conditions, and must be produced in accordance with current Good Manufacturing Practice (GMP), regulations for manufacturing/processing, packing, or holding human food. The FD&C Act also includes requirements that pertain to the labeling of food and preventive controls, as applicable. Manufacturers have a responsibility to ensure that the food they produce for the United States market is safe and complies with the FD&C Act and FDA's implementing regulations. In Canada, insects are subject to the same standards and guidelines as other foods sold in stores or online.
antiparallel The contrasting orientations of the two strands of a double-stranded nucleic acid (and more generally any pair of biopolymers) which are parallel to each other but with opposite directionality. For example, the two complementary strands of a DNA molecule run side-by-side but in opposite directions with respect to chemical numbering conventions, with one strand oriented 5'-to-3' and the other 3'-to-5'.
When one molecule of a base via complete ionization produces one hydroxide ion, the base is said to be a monoacidic or monoprotic base. Examples of monoacidic bases are: Sodium hydroxide, potassium hydroxide, silver hydroxide, ammonium hydroxide, etc.
Sources: en.wikipedia.org
=== Diet === Research by Alan Ebringer at King's College in London, beginning in the 1980s, implicates overgrowth of the bacterium Klebsiella pneumoniae in the symptoms of ankylosing spondylitis. The body produces antibodies that attack Klebsiella pneumoniae. Enzymes made by the bacterium resemble human proteins, including three types of collagen (I, III, IV) and the HLA-B27 complex of glycoproteins. The antibodies therefore attack these human proteins, producing the symptoms of ankylosing spondylitis. Ebringer and others recommend low-starch or no-starch diets.
== Phytochemicals == Cupuaçu flavors derive from its phytochemicals, such as tannins, glycosides, theograndins, catechins, quercetin, kaempferol and isoscutellarein. It also contains theacrine, caffeine, theobromine, and theophylline as found in cacao, although with a much lower amount of caffeine.
It is also formed by the degradation of precursors such as some fluorotelomers. PFOA is used as a surfactant because it can lower the surface tension of water more than hydrocarbon surfactants while having exceptional stability due to having perfluoroalkyl tail group. The stability of PFOA is desired industrially but is a cause of concern environmentally. The primary manufacturer of perfluorooctanesulfonic acid (PFOS), 3M, began a production phase-out in 2002 in response to concerns expressed by the U.S. Environmental Protection Agency (EPA). Eight other companies agreed to gradually phase out the manufacturing of the chemical by 2015. By 2014, EPA had listed PFOA and perfluorooctanesulfonates (salts of perfluorooctanesulfonic acid, PFOS) as emergent contaminants:
In addition to grains, such as corn, rice, or wheat, vegetable protein also occurs in legumes, which include beans and peanuts. Grains tend to be deficient in tryptophan and lysine, whereas legumes lack methionine Thus a meal combining grains and legumes such as the Mexican peasant dish of corn tortillas and refried beans is basically complete in amino acid content.
It is found in certain hallucinogenic snuffs and in Incilius alvarius (Bufo alvarius; Colorado River toad) toad venom. 5-MeO-DMT is about 5- to 20-fold more potent by weight than DMT. It produces atypical psychedelic effects, including powerful experiences but a relative absence of visual effects, with these experiences often described as "whiteouts". 5-MeO-DMT is usually smoked similarly to DMT and has been described as the "most powerful" known psychedelic or as the "Mount Everest" of psychedelics. The atypical effects of 5-MeO-DMT are thought to be related to strong concomitant activity at the serotonin 5-HT1A receptor. 2C-B (2,5-dimethoxy-4-bromophenethylamine) is a substituted phenethylamine first synthesized in 1974 by Alexander Shulgin. 2C-B has been described as both a psychedelic and a mild entactogen, with its psychedelic effects increasing and its entactogenic effects decreasing with dose. 2C-B is the most well-known compound in the 2C family, their general structure being discovered as a result of modifying the structure of mescaline. It is also the most widely used synthetic phenethylamine psychedelic. MDMA ("ecstasy") is sometimes said to also have weak psychedelic effects, but it acts and is classified mainly as an entactogen rather than as a hallucinogen. Certain closely related drugs like MDA and MMDA, while much less common, have greater psychedelic effects however. In addition to the above-listed psychedelics, there are hundreds of other much lesser-known psychedelic drugs.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.